Drug Combo Proves Powerful Against Lung Cancer Rome NY

A two-drug combination treatment in Rome proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Atul V Butala
(315) 798-9300
807 Newell Street
Utica, NY
Faina Sherman
(315) 624-4300
1676 Sunset Ave
Utica, NY
SAMIR DESAI, MD
(315) 798-9300
807 Newell Street
Utica, NY
Alicia M Detraglia, MD
315-724-2177
6 Hampden Pl
Utica, NY
Linda Lauree Schicker, MD
315-338-0897
107 East Chestnut South
Rome, NY
Samir DeSai
(315) 798-9300
807 Newell St
Utica, NY
Margaret Nichols
(315) 361-2020
321 Genesee St
Oneida, NY
SHEILA LEMKE, MD
(315) 464-8200
603 Seneca Street
Oneida, NY
ATUL BUTALA, MD
(315) 798-9300
807 Newell Street
Utica, NY
Lisa Ann Mueller, MD
914-830-9581
1514 Genesee St Apt 50
Utica, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Delayed Prostate Cancer Therapy Rome NY
The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues.
- Exercise for Prostate Cancer Rome NY
- Fungal Infection Treatments Rome NY
- Risks for Childhood Cancer Survivors Rome NY
- Hormone Therapy for Lung Cancer Rome NY
- Side Effect Of Chemotherapy Drugs Rome NY
- Genetic Clues for Skin Cancer Therapies Rome NY
- Exercise for Breast Cancer Survival Rome NY
- Hormone Therapy for Breast Cancer Rome NY